Brian Piekos - Elicio Therapeutics Chief Officer
| ELTX Stock | 4.88 0.20 3.94% |
Executive
Brian Piekos is Chief Officer of Elicio Therapeutics
| Age | 49 |
| Address | 451 D Street, Boston, MA, United States, 02210 |
| Phone | 857-209-0050 |
| Web | https://elicio.com |
Brian Piekos Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Piekos against Elicio Therapeutics stock is an integral part of due diligence when investing in Elicio Therapeutics. Brian Piekos insider activity provides valuable insight into whether Elicio Therapeutics is net buyers or sellers over its current business cycle. Note, Elicio Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Elicio Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Piekos over a month ago Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16b-3 |
Elicio Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.968) % which means that it has lost $0.968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.5302) %, meaning that it created substantial loss on money invested by shareholders. Elicio Therapeutics' management efficiency ratios could be used to measure how well Elicio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.36 in 2024. Return On Capital Employed is likely to rise to -1.95 in 2024. At this time, Elicio Therapeutics' Other Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 30.05 in 2024, whereas Total Assets are likely to drop slightly above 20.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Bishop | Lyra Therapeutics | 62 | |
| Kevin Shaw | NextCure | 49 | |
| Erin Rudsinski | ESSA Pharma | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| Terry Schuenemeyer | ESSA Pharma | N/A | |
| MS CPA | Erasca Inc | 57 | |
| Erica Osbourne | ESSA Pharma | N/A | |
| Mustapha Parekh | Design Therapeutics | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Edna Maneval | Oric Pharmaceuticals | 64 | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Lora Pike | Sensei Biotherapeutics | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Josep Garcia | Inhibrx | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Udayan MD | NextCure | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
Management Performance
| Return On Equity | -3.53 | ||||
| Return On Asset | -0.97 |
Elicio Therapeutics Leadership Team
Elected by the shareholders, the Elicio Therapeutics' board of directors comprises two types of representatives: Elicio Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elicio. The board's role is to monitor Elicio Therapeutics' management team and ensure that shareholders' interests are well served. Elicio Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elicio Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esther Welkowsky, Senior Development | ||
| Peter DeMuth, Chief Officer | ||
| Michael DiVecchia, Senior Resources | ||
| Megan Filoon, Secretary Counsel | ||
| Joy Seymour, VP Affairs | ||
| Brian Piekos, Chief Officer | ||
| Robert Connelly, President, CEO | ||
| Prof Irvine, Consultant, CoFounder | ||
| Thian Kheoh, Senior Biometrics |
Elicio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elicio Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.53 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 50.75 M | ||||
| Shares Outstanding | 10.79 M | ||||
| Shares Owned By Insiders | 26.08 % | ||||
| Shares Owned By Institutions | 5.81 % | ||||
| Number Of Shares Shorted | 59.73 K | ||||
| Price To Book | 10.11 X | ||||
| EBITDA | (32.97 M) | ||||
| Net Income | (35.2 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.